Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1323-1329

  Rahman, Matlubur ^a   Nishiyama, Akira ^a   Guo, Peng ^a   Nagai, Yukiko ^a   Zhang, Guo Xing ^a   Fujisawa, Yoshihide ^a   Fan, Yu Yan ^a   Kimura, Shoji ^a   Hosomi, Naohisa ^a   Omori, Koji ^a   Abe, Youichi ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ALCOHOL; ALDOSTERONE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DRINKING WATER; FIBRONECTIN; MESSENGER RNA; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SODIUM CHLORIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE; HEART PROTECTION; HEART STRESS; HEART WEIGHT; HYPERALDOSTERONISM; MALE; MALIGNANT HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE VOLUME;

ADRENOMEDULLIN; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; COLLAGEN; FIBRONECTINS; HEART; HYPERTENSION; MALE; MYOCARDIUM; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDES; POTASSIUM; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RNA, MESSENGER; SODIUM;

EID: 33747593839     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.105106     Document Type: Article

References (39)

1. Beswick RA, Dorrance AM, Leite R, and Webb RC (2001) NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38:1107-1111.
2. Bos R, Mougenot N, Mediani O, Vanhoutte PM, and Lechat P (2004) Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. J Pharmacol Exp Ther 309:1160-1166.
3. Brilla CG (2000) Aldosterone and myocardial fibrosis in heart failure. Herz 25:299-306.
4. Brilla CG, Matsubara LS, and Weber KT (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A-16A.
5. Brilla CG and Weber KT (1992) Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26:671-677.
6. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, Vermeulen A, and Clement DL (1993) Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 71:17A-20A.
7. Eto T, Kato J, and Kitamura K (2003) Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regul Pept 112:61-69.
8. Hancock JT and Jones OT (1987) The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 242:103-107.
9. Iglarz M, Touyz RM, Viel EC, Amiri F, and Schiffrin EL (2004) Involvement of oxidative stress in the profibrotic action of aldosterone: interaction with the renin-angiotensin system. Am J Hypertens 17:597-603.
10. Kato K, Yin H, Agata J, Yoshida H, Chao L, and Chao J (2003) Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol 285:H1506-H1514.
11. Kawai J, Ando K, Tojo A, Shimosawa T, Takahashi K, Onozato ML, Yamasaki M, Ogita T, Nakaoka T, and Fujita T (2004) Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 109:1147-1153.
12. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, and Iwao H (1995) Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273:509-515.
13. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, and Kim CD (2002) Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51:522-527.
14. Kitamura K, Kangawa K, and Eto T (2002) Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech 57:3-13.
15. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, and Eto T (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553-560.
16. Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, and Matsuoka H (2002) Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension 40:107-113.
17. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, et al. (2005a) Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46:1039-1045.
18. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, et al. (2005b) Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16:574-575.
19. Nakano D, Hayashi T, Tazawa N, Yamashita C, Inamoto S, Okuda N, Mori T, Sohmiya K, Kitaura Y, Okada Y, et al. (2005) Chronic hypoxia accelerates the progression of atherosclerosis in apolipoprotein E-knockout mice. Hypertens Res 28:837-845.
20. Nakano D, Itoh C, Ishii F, Kawanishi H, Takaoka M, Kiso Y, Tsuruoka N, Tanaka T, and Matsumura Y (2003) Effects of sesamin on aortic oxidative stress and endothelial dysfunction in deoxycorticosterone acetate-salt hypertensive rats. Biol Pharm Bull 26:1701-1705.
21. Newaz MA and Nawal NNA (1998) Effect of α-tocopherol on lipid peroxidation and total antioxidant status in spontaneously hypertensive rats. Am J Hypertens 11:1480-1485.
22. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, Yoshihara F, Kangawa K, and Matsuoka H (2002) Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 39:1077-1082.
23. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, and Kimura G (1999) Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33:261-266.
24. Nishiyama A, Jackson KE, Majid DSA, Rahman M, and Navar LG (2006) Renal interstitial fluid ATP responses to arterial pressure and tubuloglomerular feedback activation during treatment with a calcium channel blocker. Am J Physiol 290:H772-H777.
25. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, et al. (2004) Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43:841-848.
26. Park YM, Park MY, Suh YL, and Park JB (2004) NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 313:812-817.
27. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, and Williams GH (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831-1838.
28. Rahman M, Kimura S, Nishiyama A, Hitomi H, Zhang G, and Abe Y (2004) Angiotensin II stimulates superoxide production via both angiotensin AT1A and AT1B receptors in mouse aorta and heart. Eur J Pharmacol 485:243-249.
29. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, and Pessina AC (2002) Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40:23-27.
30. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, and Pessina AC (1997) Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95:1471-1478.
31. Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kanagawa K, Kato S, Ando K, and Fujita T (2002) Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 105:106-111.
32. Soylu A, Temizhan A, Duzenli MA, Sokmen G, Koylu O, and Telli HH (2004) The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension. Jpn Heart J 45:807-821.
33. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, and Weber KT (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161:1773-1781.
34. Yoshimoto T, Fukai N, Sato R, Sugiyama T, Ozawa N, Shichiri M, and Hirata Y (2004) Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology 145:3331-3337.
35. Yoshimoto T, Gochou N, Fukai N, Sugiyama T, Shichiri M, and Hirata Y (2005) Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells. Hypertens Res 28:165-172.
36. Young M, Fullerton MJ, Dilley R, and Funder JW (1994) Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Investig 93:2578-2583.
37. Zalba G, Beaumont FJ, Jose GS, Fortuno A, Fortuno MA, Etayo JC, and Diez J (2000) vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35:1055-1061.
38. Zannad F, Alla F, Dousset B, Parez A, and Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spirolactone therapy in patients with congestive heart failure: insight from the Randomized Aldactone Evaluation Study (RALES). Circulation 102:2700-2706.
39. Zhao Y, Bell D, Smith LR, Zhao L, Devine AB, McHenry EM, Nicholls DP, and McDermott BJ (2006) Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension. J Pharmacol Exp Ther 316:1269-1281.